Firms Battle in Court Over Safety of Vaccine

BOSTON—The company that agreed to market the world's first genetically engineered pseudorabies livestock vaccine has charged the vaccine's developer with "fraudulent misrepresentation" of the vaccine's safety and efficacy. According to a claim filed November 13 in U.S. District Court in Houston, TechAmerica Group Inc. would not have entered into its agreement with Novagene Ltd. "had it known the truth with regard to such statements, representations and omissions" in the data presented on t

Written bySeth Shulman
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

According to a claim filed November 13 in U.S. District Court in Houston, TechAmerica Group Inc. would not have entered into its agreement with Novagene Ltd. "had it known the truth with regard to such statements, representations and omissions" in the data presented on the product by Novagene in 1984.

TechAmerica's claims are a response to a suit brought against it October 31 by the Houston-based Novagene. Novagene has sued TechAmerica for breach of contract, claiming that the Elwood, Kan., company failed to advertise and market the product, even though the pseudorabies vaccine had been licensed by the U.S. Department of Agriculture (USDA) and made available for sale.

TechAmerica alleges that three key safety issues were initially misrepresented by Novagene: the vaccine's, capacity for reversion to virulence, its degree of safety for pregnant sows, and the extent to which the animals can shed the vaccine virus, potentially passing it into ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies